AGL · XBRL financial data
agilon health financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (AGL's year ends in late December)
| In millions of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue from contracts with customers | 1,834 | 2,708 | 4,316 | 6,061 | 5,933 |
| General and administrative | 456 | 219 | 286 | 269 | 239 |
| Total operating expenses | 2,228 | 2,829 | — | — | — |
| Operating income (loss) | (394) | (120) | (232) | (292) | (463) |
| Interest expense | 6 | 5 | 7 | 6 | 7 |
| Income tax expense (benefit) | 1 | 2 | 1 | 1 | 1 |
| Net income (loss) | (406) | (107) | (263) | (260) | (391) |
| Weighted average shares, basic‡ millions of shares | 15 | 16 | 16 | 16 | 17 |
| Weighted average shares, diluted‡ millions of shares | 15 | 16 | 16 | 16 | 17 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (March 2026); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (AGL's year ends in late December)
| In millions of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 1,040 | 497 | 108 | 188 | 174 |
| Marketable securities | 0 | 412 | — | — | — |
| Prepaid and other current assets | 19 | 34 | 43 | 35 | 138 |
| Total current assets | 1,367 | 1,451 | 1,480 | 1,458 | 1,097 |
| Property and equipment, net | 9 | 20 | 28 | 28 | 25 |
| Right-of-use asset | 12 | 13 | 13 | 9 | 4 |
| Goodwill | 42 | 42 | 24 | 24 | 0 |
| Total assets | 1,586 | 1,697 | 1,741 | 1,734 | 1,271 |
| Current portion of long-term debt | 5 | 5 | 6 | 0 | 19 |
| Total current liabilities | 357 | 535 | 977 | 1,152 | 1,076 |
| Long-term debt | 43 | 38 | 32 | 35 | 16 |
| Lease liability, non-current | 8 | 10 | 11 | 7 | 2 |
| Total liabilities | 495 | 657 | 1,080 | 1,263 | 1,145 |
| Accumulated deficit | (958) | (1,064) | (1,327) | (1,587) | (1,978) |
| Total stockholders' equity | 1,092 | 1,041 | 662 | 471 | — |
| Total liabilities and equity | 1,586 | 1,697 | 1,741 | 1,734 | 1,271 |
| Common shares outstanding (cover page)‡ millions of shares | 16 | 17 | 16 | 16 | 17 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (March 2026); filings made before it reported them unadjusted.
Cash flows
CSVFiscal years (AGL's year ends in late December)
| In millions of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | (406) | (107) | (263) | (260) | (391) |
| Stock-based compensation | 292 | 28 | 69 | 51 | 49 |
| Depreciation and amortization | 15 | 14 | 20 | 24 | 29 |
| Net cash from operating activities | (148) | (131) | (156) | (58) | (106) |
| Purchases of property and equipment | 7 | 15 | 16 | 13 | 13 |
| Net cash from investing activities | (91) | (444) | (44) | 140 | 89 |
| Proceeds from issuing common stock | 0 | 33 | 12 | 1 | — |
| Proceeds from issuing equity | — | — | 12 | 1 | (3) |
| Share repurchases | — | — | 200 | — | — |
| Proceeds from long-term debt | 100 | 0 | 0 | — | — |
| Repayments of long-term debt | 120 | 5 | 5 | 4 | 0 |
| Net cash from financing activities | 1,154 | 28 | (193) | (3) | (3) |
| Net change in cash | — | — | (393) | 80 | (20) |
Compare with peers
SIC 8090 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8090 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| agilon health | 174 | 1,519 | 50* | 16.8M | 10-QSep 30, 2026 |
| Sotera Health | 412 | 325 | 111* | 285.6M | 10-QSep 30, 2026 |
| Progyny | 153 | 351 | 50* | 76.7M | 10-QJun 30, 2026 |
| Acadia Healthcare Company | 163 | 895 | 98* | 93.0M | 10-QSep 30, 2026 |
| Viemed Healthcare | 9.7 | 81 | 11* | 37.9M | 10-QSep 30, 2026 |
| Concentra Group Holdings Parent | 158 | 606 | 135* | 127.5M | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.